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Pharyngeal colonization prevalence rates for Streptococcus pyogenes and
Streptococcus pneumoniae in a respiratory chemoprophylaxis
intervention study using azithromycin
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Objectives A prospective assessment of the pharyngeal colonization prevalence rates for Streptococcus pyogenes
and Streptococcus pneumoniae before and after an azithromycin chemoprophylaxis intervention clinical trial in a
cohort of US Marine Corps trainees. In addition, the minimum inhibitory concentrations (MICs) for all
streptococcal isolates, for azithromycin, penicillin, erythromycin and cefotaxime are reported.
Methods Between November 1994 and March 1995, 1108 asymptomatic male US Marine Corps trainees,
located in Southern California, were randomly assigned to one of three intervention groups: (1) weekly oral
azithromycin, 500 mg (n = 362); (2) 1.2 MU benzathine penicillin G, intramuscularly once (n = 374); or (3) no
chemoprophylaxis (n = 372). Subjects provided both a pre- and post-training pharyngeal culture and microbial
analysis was conducted to determine the colonization status of each study subject.
Results The pretraining colonization prevalence was 1.2% for S. pneumoniae and 2.4% for S. pyogenes. There
was no statistical difference in pretraining prevalence between the three treatment groups for either organism.
Post-training pharyngeal cultures revealed an overall prevalence of 1.1% with no difference between treatment
arms. However, the overall post-training prevalence of S. pyogenes colonization increased to 4.8%, with the
azithromycin group having significant evidence of protection (0.7%) in comparison with the no-treatment
group (8.2%). The Etest method demonstrated no significant difference in the MIC50, MIC90, and MIC ranges
between pre- and post-training isolates for any of the tested drugs.
Conclusion The use of azithromycin as a chemoprophylactic agent to reduce the colonization and subsequent
infection of streptococcal respiratory disease among healthy adult male military recruits may be beneficial.
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INTRODUCTION
The prophylactic use of antimicrobial agents to prevent strep-
tococcal infection has been firmly established [1,2], including
the use of benzathine penicillin G (BPG) for preventing Strep-
tococcus pyogenes or Streptococcus pneumoniae among military
populations [3,4]. Over the past few years, penicillin-tolerant
and -resistant streptococcal strains have emerged world-wide
[5], limiting the use of penicillin(s) for empirical therapy or
chemoprophylaxis. In addition, penicillin(s) have limited anti-
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microbial coverage against many atypical respiratory pathogens,
e.g. Mycoplasma pneumoniae, Moraxella catarrhalis, Chlamydia
pneumoniae and Legionella pneumophila [6]. As newer anti-
microbials come onto the market, the chemoprophylaxis effi-
cacy of each drug is usually not available. Azithromycin has
been shown to be active against several different genera, includ-
ing Gram-positive and Gram-negative bacteria as well as M.
pneumoniae and C. pneumoniae [7–11].
Over the past few years, there has been an alarming increase
in the rate of respiratory disease among US Marine Corps
trainees in Southern California, especially during the winter
months [4]. Although these outbreaks are well documented,
defined etiological information is limited. The use of BPG as a
chemoprophylactic during these respiratory outbreaks has not
demonstrated a significant reduction in respiratory morbidity,
indicating that the etiological agent may not be susceptible to
penicillin(s), the chemoprophylactic methodology is inap-
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propriate or that subjects who did not receive BPG prophylaxis
remained colonized and subsequently spread the infection
[12,13]. This study describes a trial using a new macrolide class
drug as chemoprophylaxis.
METHODS AND MATERIALS
Study design
Our research group conducted a prospective, multi-arm chemo-
prophylaxis trial to determine the efficacy of using azithromycin
to prevent/reduce respiratory disease among Marine Corps
trainees located in Southern California [3]. Briefly, between
November 1994 and March 1995, 1108 asymptomatic vol-
unteers (US Marine Corps infantry training command) were
randomly assigned to one of three study groups: (1) azi-
thromycin intervention group (500 mg PO, once per week for
duration of the study) (n = 362); (2) benzathine penicillin G
intervention group (1.2 million units, IM, once upon enroll-
ment) (n = 374); and (3) a control group (n = 372), in which
no chemoprophylaxis was administered. Study subjects were
excluded from enrollment if they had a penicillin, erythromycin,
or azithromycin sensitivity or if they were taking a theophylline
preparation [3]. Upon study enrollment, all volunteers provided
7 mL of blood, had two pharyngeal swabs taken and started
interventional chemoprophylaxis. Study subjects were mon-
itored weekly for drug compliance, adverse side-effects and
signs of acute respiratory disease. Medical records of all study
volunteers were marked to alert medical providers of study
participation. At the completion date (after 63 days of training),
study subjects again provided 7 mL of blood, completed a post-
training questionnaire and had two pharyngeal swabs taken. Of
the initial volunteer group, 915 subjects provided both pre-
and post-training pharyngeal cultures, in which colonization
prevalence rates for S. pyogenes and S. pneumoniae were cal-
culated for each intervention group.
Acute disease
Acute respiratory disease was monitored for all subjects for the
duration of the study and were not excluded from final post-
training analysis. Study subjects were considered to have an
acute respiratory disease if they visited military sick call with
any of the following symptoms: sore throat, cough, difficulty
in breathing, or a physical examination consistent with a res-
piratory tract infection. In addition to the clinical work-up,
research assistants collected two throat swabs and 7 mL of blood
and administered a clinical questionnaire that collected infor-
mation on the duration of current illness, physical examination
findings, whether a chest X-ray was performed, diagnosis, anti-
biotic regimen prescribed, and coexistent medical conditions.
Microbiology
Pharyngeal swabs were inoculated onto blood agar plates con-
taining 5% sheep’s blood, incubated at 35 °C in 5% CO2 and
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read at 24 h. All plates were examined for typical streptococcal
colony morphology and hemolysis patterns. Any suspicious
colonies were re-plated for isolation and incubated at 35 °C in
5% CO2 for an additional 24 h. All b-hemolytic isolates were
tested for catalase production, susceptibility to bacitracin and
Gram stained. b-hemolytic, Gram-positive cocci that were cat-
alase negative were further identified by streptococcal antigen
grouping (Lancefield Grouping A, B, C, F, G; Difco, Detroit,
MI, USA) and biochemical analysis using API 20S (bioMer-
ieux-Vitek, Hazelwood, MO, USA). Suspicious a-hemolytic
colonies were inoculated onto fresh 5% sheep blood agar plates
and an optochin disk (BBL; Cockeysville, MD, USA) was
placed in the primary quadrant. All streptococcal plates were
incubated at 35 °C in 5% CO2 and read at 24 h. Optochin
positive isolates were re-cultured and incubated at 35 °C in 5%
CO2 for an additional 24 h. Biochemical confirmation was
conducted on all optochin-positive isolates using the API 20S.
Susceptibility testing
Antimicrobial susceptibilities (azithromycin, erythromycin,
penicillin, cefotaxime) for confirmed S. pyogenes and S. pne-
umoniae isolates were determined by the Etest (AB Biodisk,
Solna, Sweden) methodology, following manufacturers’
instructions. Antimicrobial minimum inhibitory concentration
(MIC) breakpoints used in this study were adapted from the
recommendations of the National Committee for Clinical Lab-
oratory Standards [14].
Statistical analysis
Since the expected values of each cell were greater than five,
intervention group comparisons were made with a Pearson’s
chi-square test. All statistical analysis and MIC calculations
(MIC50, MIC90 and MIC means) were determined using SAS
6.12 (SAS Institute, Cary, NC, USA).
RESULTS
Of the initial 1108 study subjects, 915 (83%) provided both a
pre- and post-training pharyngeal culture. Incomplete follow-
up was similar between all three intervention groups: 16% (59
of 362) in the azithromycin group, 22% (82 of 374) in the BPG
group and 14% (52 of 372) in the control group. Drop-outs
resulted from training attrition, drug-noncompliance and drug
side-effects [3]. In this study group, 14.5% (133 of 915) sought
medical attention for acute respiratory disease, with seven cases
of S. pyogenes (three from the BPG group and four from the
control group) and two cases of S. pneumoniae (one from the
azithromycin group and one from the control group).
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Streptococcus pyogenes
During the pretraining phase a total of 22 S. pyogenes isolates
were recovered for an overall colonization prevalence rate of
2.4% (22 of 915). There was no overall difference in the per-
centage distribution among the three intervention groups dur-
ing the pretraining phase (x2 = 1.36; P = 0.5) (Table 1). The
colonization prevalence rate was 2.3% (seven of 303) in the
azithromycin group, 1.7% (five of 292) in the penicillin group
and 3.1% (10 of 320) in the control group; indicating adequate
randomization of subjects with respect to S. pyogenes colon-
ization. During the post-training phase a total 44 S. pyogenes
isolates were recovered for an overall colonization prevalence
rate of 4.8% (44 of 915). There was a significant difference in
the percentage distribution of S. pyogenes isolates among the
three intervention groups in the post-training phase (x2 = 19.5;
P  0.001). The azithromycin group had 0.7% (two of 303),
the penicillin group had 5.5% (16 of 292) and the control group
had 8.2% (26 of 320).
Table 2 lists the MIC50, MIC90, and MIC range for each
antimicrobial tested for S. pyogenes. There was no difference
between the pre and post-training MICs for any of the inter-
vention groups, or the acutely ill subjects. The S. pyogenes
pretraining azithromycin MIC50 was 0.75 mg/L compared with
the post-training MIC50 of 0.5 mg/L and the S. pneumoniae
pretraining azithromycin MIC50 was 0.12 mg/L compared with
0.25 mg/L for the post-training MIC50. No other antibiotics
demonstrated a significant shift in either the MIC distributions
or in the MIC range for S. pyogenes. Among S. pyogenes isolates
associated with acute respiratory disease, no significant MIC
shifts were noted among any of the intervention groups.
Streptococcus pneumoniae
In the pretraining phase, a total of 11 S. pneumoniae isolates
were recovered with an overall colonization prevalence rate of
Table 1 Bacterial recovery in the pre-
and post-training comparisons for
each intervention group
Intervention group Pre
Organism (% positive) (% positive) Post
S. pyogenes Overall 2.4% (22/915) 4.8% (44/915)
Azithromycin 2.3% (7/303) 0.7% (2/303)
Penicillin 1.7% (5/292) 5.5% (16/292)
Control 3.1% (10/320) 8.2% (26/320)
x2 = 1.36 19.5
P = 0.5 0.001
S. pneumoniae Overall 1.2% (11/915) 1.1% (10/915)
Azithromycin 1.3% (4/303) 2.0% (6/303)
Penicillin 1.0% (3/292) 0.6% (2/292)
Control 1.2% (4/320) 0.7% (2/320)
x2 = 0.12 3.3
P = 0.9 0.2
x2 analysis between intervention group comparisons.
Table 1 lists all S. pneumoniae isolates recovered, listed by intervention group.
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1.2% (11 of 915). The percentage distribution of S. pneumoniae
isolates among the three intervention groups in the pretraining
phase was not significantly different (x2 = 0.12; P = 0.9). The
azithromycin group had 1.3% (four of 303); there was 1.0%
(three of 292) in the BPG group and 1.2% (four of 320) in the
control group, again demonstrating proper randomization with
respect to S. pneumoniae. The overall colonization prevalence
rate for the post-training phase was 1.1% (10 of 915). The
percentage distribution of S. pneumoniae isolates in the post-
training phase consisted of 2% (six of 303) for the azithromycin
group, 0.6% (two of 292) for the BPG group and 0.7% (2 of
320) for the control group, with no significant difference among
the three groups (x2 = 3.3; P = 0.2).
Table 3 lists the MIC50, MIC90 and MIC range for each drug
tested for S. pneumoniae among all three intervention groups.
There was a slight MIC upward shift in the S. pneumoniae
azithromycin MICs from pre to post-training for all three
groups. It is unlikely that prophylactic azithromycin is driving
this shift, since it consistently appears throughout all three
groups. This may indicate that either some unknown factor is
promoting a slight resistance or that the shift is an aberration
due to the small number of isolates tested.
DISCUSSION
The focus of this study was to access pharyngeal colonization
prevalence rates and MICs of two major bacterial etiologic
agents associated with respiratory disease among US Marine
Corps trainees undergoing a chemoprophylaxis trial. There
appeared to be a significant reduction in the post-training
colonization prevalence rate for S. pyogenes in the azithromycin
group relative to the BPG and control group. There was no
difference between the pre- and post-training colonization
prevalence rates for any of the intervention groups with respect
to S. pneumoniae.
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The MICs for all isolates did not show antimicrobial resist-
ance to penicillin, erythromycin, azithromycin or cefotaxime,
nor was there a significant shift toward acquired/selected anti-
microbial resistance in any of the intervention groups during
the 63 days of training. However, the paucity of isolates reco-
vered in all groups may be masking the true antimicrobial
patterns and/or the timeframe of this chemoprophylaxis inter-
vention was too short to elicit a true azithromycin resistance-
shift. An azithromycin trachoma treatment study conducted
among a remote group of Australian Aborginies [15] found a
temporary increase in the rates of S. pneumoniae azithromycin
resistance following treatment. However, these rates rapidly
subsided to pretreatment levels after 180 days, possibly dem-
onstrating the failure of antimicrobial usage pressures to select
stable populations of resistant S. pneumoniae in this human popu-
lation. However, the remote study population used may sig-
nificantly differ from other antibiotic-using human populations.
Further long-term azithromycin chemoprophylaxis studies
must be conducted to ascertain trends in antimicrobial resist-
ance.
The significant reduction in S. pyogenes colonization among
the azithromycin intervention group, relative to the BPG and
control groups, was remarkable. It is reasonable to argue that
the decrease in colonization could be attributable to the chemo-
prophylactic use of weekly azithromycin. The increase in
colonization prevalence rates among the BPG and control
groups demonstrates the ineffectiveness of a single dose of BPG
as a long-term chemoprophylaxis against S. pyogenes. This find-
ing is consistent with previously published reports [16]. Table 4
lists the five subjects who were S. pyogenes-positive in both the
pre- and post-training; three in the penicillin group and two in
the control group. It was not determined whether each subject
remained colonized with the same isolate throughout the trial.
However, four of the five MIC patterns obtained for the isolates
in both the pre- and post-training were different enough to
suspect that the isolates were different.
The colonization prevalence rates for S. pneumoniae did not
demonstrate a significant shift from pre- to post-training in any
of the groups. In the azithromycin group, there was a slight
Table 4 Streptococcus pyogenes
minimum inhibitory
concentrations (MICs, mg/L) for
colonized subjects at the beginning
and end of 63 days of training
Pre-training MICs Post-training MICs
Subject no. Study arm AZ ERY PEN CFT AZ ERY PEN CFT
1 BPG 0.75 0.125 0.012 0.032 1.0 0.125 0.016 0.032
2 BPG 1.0 0.125 0.016 0.023 1.5 0.125 0.125 0.38
3 BPG 0.75 0.125 0.016 0.032 1.5 0.38 0.064 0.19
4 Control 2.0 0.25 0.023 0.032 0.38 0.094 0.032 0.047
5 Control 0.75 0.064 0.016 0.032 0.75 0.125 0.023 0.75
All MICs were determined using the Etest method.
AZ, azithromycin; ERY, erythromycin; PEN, penicillin; CFT, cefotaxime.
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increase in the number of isolates recovered from pre- to post-
training (four of 303 versus six of 303). It is unlikely that this
increase reflects lack of chemoprophylaxis activity against S.
pneumoniae, but more likely is a numerical instability due to the
low prevalence of S. pneumoniae in this study. The BPG and
control groups demonstrated a nonsignificant reduction in
absolute number of isolates recovered. It is likely that these
pre- and post-training colonization prevalence rates may be a
sampling artifact due to the very low number of S. pneumoniae
isolates recovered in the study. Additional studies, with a larger
study base or during a S. pneumoniae epidemic, may be necessary
to validate the use of azithromycin chemoprophylaxis. There
were no subjects who remained positive from the pre- to post-
training in any of the intervention groups. This may indicate
that initial chemoprophylaxis with either azithromycin or BPG
eradicated colonization or that there was a spontaneous loss of
colonization over the duration of the study.
The chemoprophylactic use of azithromycin for the pre-
vention of S. pyogenes in our study group appeared to be ben-
eficial. There was no evidence of S. pyogenes colonization
among patients with acute respiratory disease and there was a
large decrease in the post-training colonization prevalence rate.
The efficacy of azithromycin for the prevention of S. pneu-
moniae was not as clear. There was one acute case of S. pneu-
moniae and the colonization prevalence rate increased in the
post-training collection.
These results may be biased by the fact that S. pyogenes has a
higher overall prevalence, has a very defined set of clinical
symptoms and is easier to diagnose and detect than S. pneu-
moniae. It is also possible that the low prevalence of S. pneu-
moniae described in this study may simply reflect an inap-
propriate collection of the micro-organism.
This study evaluated two separate point prevalence ‘snap-
shots’ before and after the administration of chemoprophylaxis.
This precludes the determination of true incidence rates of S.
pyogenes and S. pneumoniae respiratory disease among our study
group. The calculated colonization prevalence rates for S. pyog-
enes and S. pneumoniae may overestimate the actual colonization
prevalence in the age- and sex-matched general population,
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due to their crowded occupational conditions (US Marine
Corps infantry), but may be appropriate for populations with
similar living conditions and/or occupations.
BPG chemoprophylaxis was given only once whereas azi-
thromycin was administered weekly. A single dose of BPG is
the standard of care for respiratory disease chemoprophylaxis in
military populations [3]. These data suggest such a one-time
dose is ineffective. A previous report demonstrated that effective
prophylactic levels of BPG may subside as quickly as 3 weeks
after administration [17].
Another issue that was not addressed directly but could be
inferred is that the prevalence of respiratory disease(s) increases
over the winter months. Thus the increase in colonization rates
may have been a seasonal reflection of the winter respiratory
disease spike. However, if the winter spike was independent of
chemoprophylaxis, one would expect to see an increase in all
three groups and this was not the case for S. pyogenes. There
was an increase in the penicillin and controls groups compared
with a decrease in the azithromycin group. It is possible that
azithromycin has good activity against S. pyogenes pharyngeal
colonization, whereas BPG does not or that the critical level of
BPG was not maintained during the study. The prevalence of
respiratory disease in military recruit populations increases as
time in training increases. This may be related to crowded
living and working conditions, seasonal variation or individuals
not receiving prophylaxis providing bacterial reservoirs for sus-
tained transmission [13].
The development and/or selection of antimicrobial resist-
ance is of special interest in any chemoprophylaxis program. In
this study, it appears that resistance was not selected for by any
of the antimicrobials used. From the data presented here and
after considering the small number of isolates in each group,
the use of azithromycin as a chemoprophylactic agent may
still be beneficial in reducing the prevalence and incidence of
streptococcal-based respiratory disease. This may be especially
true among defined male populations housed in close quarters
and that the use of azithromycin poses only a minimal risk of
resistance selection.
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